Clinical Trials

The purpose of this study is to investigate the occurrance and disease characteristics of chronic hives lasting longer than 6 weeks and that do not have an identifiable trigger.

The purpose of this study is to investigate the potential effectiveness of dupilumab in the treatment of moderate-to-severe, chronic hepatic pruritus.

The purpose of this study is to develop a psoriasis-specific tool to assess the quality of life of the parents and caregivers of children with psoriasis.

The purpose of this study is investigating the safety and effectiveness of Volixibat in the treatment of cholestatic pruritis. 

The purpose of this study is to identify the long-term occurrence of non-melanoma skin cancers in patients who had ultraviolet light therapy as a child in the years 1970 to 2000.

This study is being conducted to evaluate the efficacy, safety and tolerability of GSK2330672 administration for the treatment of pruritus (itch) in participants with primary biliary cholangitis (PBC). Participants will be treated with either placebo or one of the 4 dose regimens of GSK2330672 (20 milligram [mg], 90 mg or 180 mg taken once daily or 90 mg twice daily). Subjects on GSK2330672 will also receive placebo tablets to maintain blinding. The total duration of a subject's participation will be up to 45 days of screening and 24 weeks of study including follow-up.

This multi-center, double-blind, vehicle-controlled, randomized crossover design study will evaluate the safety and efficacy of topically applied naloxone lotion, 0.5%, for the treatment of pruritus in patients with the mycosis fungoides (MF) or Sézary syndrome (SS) Forms of Cutaneous T-cell Lymphoma (CTCL). This study will also determine if there is systemic absorption of the drug in a subset of subjects and if so, describe the range and mean plasma levels reached after two weeks of three time daily (TID) dosing. Funding Source - FDA OOPD